Therapeutic antibody for RSV

Ended Project Grant Awarded Last action

Award ID
R44AI122360
Recipient
Awarding agency
Obligated
$7,761,452

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date
Originally
Funding
  • $6,763,748.00 Federal
  • $997,704.00 Non-federal
Place of performance
California, USA

Award details come from USAspending.gov.

Transactions

Action Federal Non-federal Date
Amendment $0 $0
Amendment $0 $0
Amendment $1,000,000 $0
Amendment $1,000,000 $0
Amendment $997,704 $0
Amendment $997,704 $0
Amendment $1,000,000 $0
Amendment $1,000,000 $0
Amendment $1,000,000 $0
Amendment $1,000,000 $0
Amendment $997,704 $0
Amendment -$1,000,000 $0
Amendment -$1,000,000 $0
Amendment -$997,704 $0
Amendment -$997,704 $0
Amendment -$1,000,000 $0
Amendment -$1,000,000 $0
Amendment -$997,704 $0
Amendment -$1,000,000 $0
Amendment -$1,000,000 $0
Amendment $997,704 $0
Amendment $997,704 $997,704
Amendment $1,000,000 $0
Amendment Therapeutic antibody for RSV IIB $1,000,000 $0
Amendment $0 $0
Amendment $0 $0
Amendment $1,499,589 $0
Original award $1,268,751 $0
Show all 28

Quick answers

Who received award R44AI122360?

R44AI122360 was awarded to Trellis Bioscience, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on February 1, 2016.

How much is award R44AI122360 worth?

$7,761,452 has been obligated on R44AI122360: $6,763,748 in federal funding and $997,704 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award